AR030416A1 - COMPUESTO DERIVADO HALOGENADO DEL ACIDO 2-AMINO-3,4 HEPTENOICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE Y SU USO EN LA FABRICACION DE UN MEDICAMENTO uTIL COMO INHIBIDOR DE LA OXIDO NITRICO SINTETASA - Google Patents

COMPUESTO DERIVADO HALOGENADO DEL ACIDO 2-AMINO-3,4 HEPTENOICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE Y SU USO EN LA FABRICACION DE UN MEDICAMENTO uTIL COMO INHIBIDOR DE LA OXIDO NITRICO SINTETASA

Info

Publication number
AR030416A1
AR030416A1 ARP010101736A ARP010101736A AR030416A1 AR 030416 A1 AR030416 A1 AR 030416A1 AR P010101736 A ARP010101736 A AR P010101736A AR P010101736 A ARP010101736 A AR P010101736A AR 030416 A1 AR030416 A1 AR 030416A1
Authority
AR
Argentina
Prior art keywords
nitric oxide
halo
amino
manufacture
alkynyl
Prior art date
Application number
ARP010101736A
Other languages
English (en)
Inventor
Donald W Hansen Jr
Keith R Webber Jr
Mihaly Toti
Alok Awasthi
Barnett S Pitzele
Mahima Trivedi
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of AR030416A1 publication Critical patent/AR030416A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/14—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/04—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/04—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D263/06—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by oxygen atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)

Abstract

Derivado halogenado del ácido 2-amino-3,4 heptenoico util como inhibidor de oxido nitrico sintetasa, que tiene la formulas 1, 2 o 3 o una sal aceptable para uso farmacéutico del mismo, donde: R1 se selecciona del grupo formado por hidrogeno, alquilo, alquenilo, alquinilo, y halo donde todos menos hidrogeno y halo pueden ser sustituidos por uno o más hidroxi, alquilo, alquenilo, alquinilo, alcoxi, y halo; R2 se selecciona del grupo formado por hidrogeno, alquilo, alquenilo, alquinilo, y halo donde todos menos hidrogeno y halo pueden ser sustituidos por uno o más hidroxi, alquilo, alquenilo, alquinilo, alcoxi, y halo; con la condicion de que al menos entre R1 o R2 debe contener un halogeno. También se revelan composiciones farmacéuticas que contienen dichos compuestos y el uso de dichos compuestos y composiciones en la fabricacion de un medicamento util para la inhibicion de la síntesis de oxido nítrico en un sujeto que necesite tal inhibicion, especialmente para inhibir selectivamente el oxido nitríco producido por la oxido nítrico sintetasa inducible con preferencia sobre el oxido nítrico producido por las formas constitutivas de la oxido nítrico sintetasa.
ARP010101736A 2000-04-13 2001-04-11 COMPUESTO DERIVADO HALOGENADO DEL ACIDO 2-AMINO-3,4 HEPTENOICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE Y SU USO EN LA FABRICACION DE UN MEDICAMENTO uTIL COMO INHIBIDOR DE LA OXIDO NITRICO SINTETASA AR030416A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19702700P 2000-04-13 2000-04-13

Publications (1)

Publication Number Publication Date
AR030416A1 true AR030416A1 (es) 2003-08-20

Family

ID=22727711

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010101736A AR030416A1 (es) 2000-04-13 2001-04-11 COMPUESTO DERIVADO HALOGENADO DEL ACIDO 2-AMINO-3,4 HEPTENOICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE Y SU USO EN LA FABRICACION DE UN MEDICAMENTO uTIL COMO INHIBIDOR DE LA OXIDO NITRICO SINTETASA

Country Status (6)

Country Link
US (1) US6586471B1 (es)
EP (1) EP1282420A4 (es)
JP (1) JP2003530412A (es)
AR (1) AR030416A1 (es)
AU (1) AU2001255393A1 (es)
WO (1) WO2001078654A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1426060A4 (en) * 2001-09-10 2004-12-01 Ono Pharmaceutical Co REMEDIES FOR ALLERGIC DISEASES
BR0313204A (pt) * 2002-08-02 2005-06-28 Pharmacia Corp Métodos para tratamento e prevenção de condições gastrointestinais
WO2005110396A2 (en) 2004-04-28 2005-11-24 Uab Research Foundation Nitrated lipids and methods of making and using thereof
DK2180787T3 (da) 2007-08-01 2014-02-03 Univ Pittsburgh Nitrooliesyremodulering af type ii-diabetes
EP2280928B1 (en) 2008-05-01 2018-07-25 Complexa Inc. Vinyl substituted fatty acids
US20140024713A1 (en) 2008-06-19 2014-01-23 University Of Utah Research Foundation Use of nitrated lipids for treatment of side effects of toxic medical therapies
WO2009155439A2 (en) 2008-06-19 2009-12-23 University Of Utah Research Foundation Use of nitrated lipids for treatment of side effects of toxic medical therapies
EP2459189A4 (en) 2009-07-31 2013-01-16 Univ Pittsburgh FATTY ACIDS AS ANTI-INFLAMMATORY ACTIVE SUBSTANCES
WO2011041639A2 (en) 2009-10-02 2011-04-07 Miller Raymond A Heteroatom containing substituted fatty acids
WO2013028501A1 (en) 2011-08-19 2013-02-28 The University Of Utah Research Foundation Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system
CN112010861A (zh) 2015-07-07 2020-12-01 H.隆德贝克有限公司 用于治疗外周疾病的具有咪唑并三嗪酮骨架和咪唑并吡嗪酮骨架的pde9抑制剂
CN113440506A (zh) 2015-10-02 2021-09-28 康普莱克夏公司 使用治疗有效量的活化脂肪酸预防、治疗和逆转疾病

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4267374A (en) * 1977-07-01 1981-05-12 Merrell Toraude Et Compagnie Derivatives of amines and amino acids
AU636713B2 (en) 1990-02-26 1993-05-06 Merrell Dow Pharmaceuticals Inc. Inhibitors of nitric oxide biosynthesis
US5132453A (en) 1991-03-22 1992-07-21 Cornell Research Foundation, Inc. N6 -(hydrazinoiminomethyl)lysine and method of inhibiting nitric oxide formation in body
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
GB9127376D0 (en) * 1991-12-24 1992-02-19 Wellcome Found Amidino derivatives
GB9203347D0 (en) 1992-02-17 1992-04-01 Wellcome Found Hypolipidaemic compounds
EP0670720A1 (en) 1992-11-27 1995-09-13 The Wellcome Foundation Limited Enzyme inhibitors
WO1994014780A1 (en) 1992-12-18 1994-07-07 The Wellcome Foundation Limited Pyrimidine, pyridine, pteridinone and indazole derivatives as enzyme inhibitors
AU688811B2 (en) 1993-10-21 1998-03-19 G.D. Searle & Co. Amidino derivatives useful as nitric oxide synthase inhibitors
DK0724435T3 (da) 1993-10-21 2002-11-25 Searle & Co Amidinoderivater, der er nyttige som nitrogenoxid-synthase-inhibitorer
GB9405211D0 (en) 1994-03-17 1994-04-27 Deas Alexander R Noise cancellation apparatus
DK0751930T3 (da) 1994-03-24 2000-04-17 Searle & Co Amidinoderivater anvendelige som nitrogenoxid-synthase-inhibitorer
US5994391A (en) 1994-09-13 1999-11-30 G.D. Searle And Company Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US5684008A (en) 1994-11-09 1997-11-04 G. D. Searle & Co. Aminotetrazole derivatives useful as nitric oxide synthase inhibitors
CA2216882A1 (en) 1995-04-20 1996-10-24 G.D. Searle & Co. Cyclic amidino agents useful as nitric oxide synthase inhibitors
CN1190390A (zh) 1995-05-10 1998-08-12 G.D.瑟尔公司 由环状脒衍生的氧化氮合成酶抑制剂
GB9516709D0 (en) 1995-08-15 1995-10-18 Zeneca Ltd Medicament
US5830917A (en) 1995-09-11 1998-11-03 G. D. Searle & Co. L-N6 -(1-iminoethyl) lysine derivatives useful as nitric oxide synthase inhibitors
US5945408A (en) 1996-03-06 1999-08-31 G.D. Searle & Co. Hydroxyanidino derivatives useful as nitric oxide synthase inhibitors
US5981511A (en) 1996-03-06 1999-11-09 G.D. Searle & Co. Hydroxyamidino derivatives useful as nitric oxide synthase inhibitors
WO1999029865A2 (en) 1997-12-12 1999-06-17 The Rockefeller University A protein belonging to the tnf superfamily, nucleic acids encoding same, and methods of use thereof
SK13012000A3 (sk) 1998-03-11 2001-06-11 G. D. Searle & Co. Halogenované deriváty amidinoaminokyselín použiteľné ako inhibítory no-syntázy

Also Published As

Publication number Publication date
AU2001255393A1 (en) 2001-10-30
US6586471B1 (en) 2003-07-01
WO2001078654A2 (en) 2001-10-25
JP2003530412A (ja) 2003-10-14
EP1282420A4 (en) 2004-12-29
WO2001078654A3 (en) 2002-08-01
EP1282420A2 (en) 2003-02-12

Similar Documents

Publication Publication Date Title
AR033359A1 (es) Compuesto amidino, composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento para inhibir la sintesis de oxido nitrico
AR034120A1 (es) Compuesto derivado halogenado del acido 2-amino-4,5 heptenoico, composicion farmaceutica que lo comprende y el uso de dicho compuesto y dicha composicion en la fabricacion de un medicamento para inhibir o modular la sintesis de acido nitrico
PE20080093A1 (es) Inhibidores de la replicacion del virus de la inmunodeficiencia humana
CO6260076A2 (es) Derivados de uracilo o timina para el tratamiento de la hepatitis c
AR032360A1 (es) Compuesto derivado de acido homoiminopiperidinil hexanoico, composicion farmaceutica que lo comprende y compuestos intermediarios que se usan en su preparacion
PA8493201A1 (es) Uso de inhibidores de la sorbitol deshidrogenasa
AR030416A1 (es) COMPUESTO DERIVADO HALOGENADO DEL ACIDO 2-AMINO-3,4 HEPTENOICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE Y SU USO EN LA FABRICACION DE UN MEDICAMENTO uTIL COMO INHIBIDOR DE LA OXIDO NITRICO SINTETASA
ECSP055671A (es) Nuevas quinazolinonas espirocondensadas y su uso como inhibidores de la fosfodiesteresa
CL2004000917A1 (es) Compuestos derivados de tiazol; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de enfermedades mediadas por 3-cinasa de dosfatidilnositol tal como enfermedades respiratorias, alergias, artritis reumatoide, osteoa
AR055076A1 (es) Derivados de1,1-dioxido de 1,4-benzotiazepina,procedimiento para prepararlos,composiciones farmaceuticas que los contienen y usos en terapeutica.
AR060545A1 (es) Compuestos de benzoaxol y benzotiazol 6-0- sustituidos y metodos de inhibicion de la senalizacion de csf-1r. composiciones farmaceuticas
MX2007013065A (es) Derivados de dihidrobenzofurano y usos de los mismos.
PE20010126A1 (es) Pirrolotriazinas como inhibidores de cinasas
UY29182A1 (es) "derivados de bencenosulfonamidas sustituídas, composiciones que las contienen, procedimientos de preparación y aplicaciones"
AR036248A1 (es) Derivados de 2h-piridazin-3-ona, composiciones farmaceuticas que los contienen y un proceso para la preparacion de dichos derivados y el uso de dichos derivados para la preparacion de una composicion farmaceutica
UY27320A1 (es) Nuevas composiciones farmacéuticas
UY31419A1 (es) Nueva forma cristalina vi de la agomelatina, su procedimiento de preparacion y las composiciones farmacéuticas que la contienen
ECSP088149A (es) 3-acilaminobenzanilidas insecticidas
MY163503A (en) Aerosol formulations for the inhalation of beta agonists
AR019790A2 (es) Compuestos derivados de la eritromicina, composiciones que los contienen. uso para preparar un medicamento
NO20052520D0 (no) Nye sulfamider
BRPI0408353A (pt) composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto
DE602006017724D1 (de) Salicylsäurederivate
BRPI0408240A (pt) composto, utilização de um composto e composição farmacêutica
CR20220014A (es) Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmacéuticas que los contienen y sus usos como agentes proapoptóticos

Legal Events

Date Code Title Description
FB Suspension of granting procedure